# A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

> **NCT04073680** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Petra Pharma** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer
- Endometrial Cancer
- Lung Cancer
- Colo-rectal Cancer
- Head and Neck Cancer

## Interventions

- **DRUG:** Serabelisib
- **DRUG:** Canagliflozin 300mg

## Key facts

- **NCT ID:** NCT04073680
- **Lead sponsor:** Petra Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2021-07-15
- **Final completion:** 2021-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04073680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04073680, "A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04073680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*